COLGATE PALMOLIVE COCL
COLGATE PALMOLIVE CO Segments Disclosure
Segment Information
(1) Long-lived assets include Property, plant and equipment, net and lease right-of-use assets.
The Company operates in two product segments: Oral, Personal and Home Care; and Pet Nutrition.
The operations of the Oral, Personal and Home Care product segment are managed geographically in five reportable operating segments: North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.
The Company evaluates segment performance based on several factors, including Operating profit. The Company uses Operating profit as a measure of operating segment performance because it excludes the impact of Corporate-driven decisions related to interest expense and income taxes. The Chairman of the Board, President and Chief Executive Officer has been determined to be the Company’s Chief Operating Decision Maker and he uses Operating Profit to assess performance and to allocate resources for each of the reportable operating segments in the budgeting and forecasting process. Asset information by segment is not utilized for purposes of assessing performance or allocating resources, and therefore such information has not been presented.
The accounting policies of the operating segments are generally the same as those described in Note 2, Summary of Significant Accounting Policies. Intercompany sales have been eliminated. Corporate operations include costs related to stock options and restricted stock units, research and development costs, Corporate overhead costs, restructuring and related implementation charges and gains and losses on sales of non-core product lines and assets. The Company reports these items within Corporate operations as they relate to Corporate-based responsibilities and decisions and are not included in the internal measures of segment operating performance used by the Company to measure the underlying performance of the operating segments.
Approximately two-thirds of the Company’s Net sales are generated from markets outside the United States, with approximately 45% of the Company’s Net sales coming from emerging markets (which consist of Latin America, Asia (excluding Japan), Africa/Eurasia and Central Europe). Oral, Personal and Home Care sales to Walmart, Inc. and its affiliates represent approximately 11% of the Company’s Net sales in each of the years 2025, 2024 and 2023. No other customer represented more than 10% of Net sales in any period presented.
In 2025, Corporate Operating profit included goodwill and intangible assets impairment charges of $919, charges resulting from the ERISA litigation matter and the Strategic Growth and Productivity Program of $99 and $13, respectively, and acquisition-related costs of $9. In 2024, Corporate Operating profit included charges resulting from the 2022 Global Productivity Initiative of $85. In 2023, Corporate Operating profit included charges resulting from the 2022 Global Productivity Initiative of $27 and product recall costs of $25.
| 2025 | |||||||||||||||||
| Net sales | Cost of Sales | Selling, general and administrative expenses | Other (income) expense, net (3) | Operating Profit | |||||||||||||
| Reportable Segments | |||||||||||||||||
| Oral, Personal and Home Care | |||||||||||||||||
North America(1) | $ | 4,045 | $ | 1,589 | $ | 1,626 | $ | 47 | $ | 784 | |||||||
| Latin America | 4,776 | 2,107 | 1,268 | (11) | 1,411 | ||||||||||||
| Europe | 2,962 | 1,099 | 1,087 | 28 | 748 | ||||||||||||
| Asia Pacific | 2,814 | 1,067 | 1,013 | (27) | 760 | ||||||||||||
| Africa/Eurasia | 1,172 | 465 | 436 | 16 | 255 | ||||||||||||
| Total Oral, Personal and Home Care | 15,769 | 3,959 | |||||||||||||||
Pet Nutrition(2) | 4,613 | 1,818 | 1,717 | 14 | 1,064 | ||||||||||||
| Reconciliation with Total Company Operating Profit | |||||||||||||||||
| Corporate | (1,717) | ||||||||||||||||
| Total | $ | 20,382 | $ | 3,306 | |||||||||||||
Note: Table may not sum due to rounding.
(1) Net sales in the United States for Oral, Personal and Home Care were $3,596 in 2025.
(2) Net sales in the United States for Pet Nutrition were $3,062 in 2025.
(3) Refer to Note 17, Supplemental Income Statement for information related to Other (income) expense, net.
| 2024 | |||||||||||||||||
| Net sales | Cost of Sales | Selling, general and administrative expenses | Other (income) expense, net (3) | Operating Profit | |||||||||||||
| Reportable Segments | |||||||||||||||||
| Oral, Personal and Home Care | |||||||||||||||||
North America(1) | $ | 4,113 | $ | 1,571 | $ | 1,668 | $ | 36 | $ | 839 | |||||||
| Latin America | 4,782 | 1,933 | 1,328 | (5) | 1,526 | ||||||||||||
| Europe | 2,770 | 1,050 | 1,031 | 31 | 658 | ||||||||||||
| Asia Pacific | 2,858 | 1,078 | 997 | (30) | 812 | ||||||||||||
| Africa/Eurasia | 1,095 | 432 | 395 | 16 | 253 | ||||||||||||
| Total Oral, Personal and Home Care | 15,618 | 4,088 | |||||||||||||||
Pet Nutrition(2) | 4,483 | 1,869 | 1,641 | 8 | 965 | ||||||||||||
| Reconciliation with Total Company Operating Profit | |||||||||||||||||
| Corporate | (784) | ||||||||||||||||
| Total | $ | 20,101 | $ | 4,268 | |||||||||||||
Note: Table may not sum due to rounding.
(1) Net sales in the United States for Oral, Personal and Home Care were $3,640 in 2024.
(2) Net sales in the United States for Pet Nutrition were $3,059 in 2024.
(3) Refer to Note 17, Supplemental Income Statement for information related to Other (income) expense, net.
| 2023 | |||||||||||||||||
| Net sales | Cost of Sales | Selling, general and administrative expenses | Other (income) expense, net (3) | Operating Profit | |||||||||||||
| Reportable Segments | |||||||||||||||||
| Oral, Personal and Home Care | |||||||||||||||||
North America(1) | $ | 4,091 | $ | 1,588 | $ | 1,594 | $ | 37 | $ | 871 | |||||||
| Latin America | 4,640 | 1,977 | 1,241 | 5 | 1,417 | ||||||||||||
| Europe | 2,571 | 1,069 | 899 | 31 | 573 | ||||||||||||
| Asia Pacific | 2,782 | 1,108 | 925 | (18) | 767 | ||||||||||||
| Africa/Eurasia | 1,083 | 442 | 377 | 9 | 254 | ||||||||||||
| Total Oral, Personal and Home Care | 15,167 | 3,882 | |||||||||||||||
Pet Nutrition(2) | 4,290 | 1,964 | 1,493 | 26 | 806 | ||||||||||||
| Reconciliation with Total Company Operating Profit | |||||||||||||||||
| Corporate | (704) | ||||||||||||||||
| Total | $ | 19,457 | $ | 3,984 | |||||||||||||
Note: Table may not sum due to rounding.
(1) Net sales in the United States for Oral, Personal and Home Care were $3,625 in 2023.
(2) Net sales in the United States for Pet Nutrition were $2,918 in 2023
(3) Refer to Note 17, Supplemental Income Statement for information related to Other (income) expense, net.
| 2025 | 2024 | 2023 | ||||||||||||||||||
| Capital expenditures | ||||||||||||||||||||
| Oral, Personal and Home Care | ||||||||||||||||||||
| North America | $ | 65 | $ | 52 | $ | 46 | ||||||||||||||
| Latin America | 141 | 126 | 146 | |||||||||||||||||
| Europe | 63 | 63 | 44 | |||||||||||||||||
| Asia Pacific | 80 | 64 | 65 | |||||||||||||||||
| Africa/Eurasia | 12 | 12 | 10 | |||||||||||||||||
| Total Oral, Personal and Home Care | 361 | 317 | 311 | |||||||||||||||||
| Pet Nutrition | 88 | 143 | 301 | |||||||||||||||||
| Corporate | 115 | 101 | 93 | |||||||||||||||||
| Total Capital expenditures | $ | 564 | $ | 561 | $ | 705 | ||||||||||||||
| 2025 | 2024 | 2023 | ||||||||||||||||||
| Depreciation and amortization | ||||||||||||||||||||
| Oral, Personal and Home Care | ||||||||||||||||||||
| North America | $ | 123 | $ | 124 | $ | 116 | ||||||||||||||
| Latin America | 106 | 100 | 98 | |||||||||||||||||
| Europe | 66 | 65 | 65 | |||||||||||||||||
| Asia Pacific | 80 | 81 | 84 | |||||||||||||||||
| Africa/Eurasia | 10 | 8 | 9 | |||||||||||||||||
| Total Oral, Personal and Home Care | 385 | 378 | 372 | |||||||||||||||||
| Pet Nutrition | 144 | 132 | 101 | |||||||||||||||||
| Corporate | 101 | 95 | 94 | |||||||||||||||||
| Total Depreciation and amortization | $ | 630 | $ | 605 | $ | 567 | ||||||||||||||
| 2025 | 2024 | |||||||||||||
Long-lived assets(1) | ||||||||||||||
| United States | $ | 2,663 | $ | 2,728 | ||||||||||
| International | 2,528 | 2,223 | ||||||||||||
| Total Long-lived assets | $ | 5,191 | $ | 4,951 | ||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 23, 2026 | Showing above |
| 2024 | Feb 13, 2025 | |
| 2023 | Feb 15, 2024 | |
| 2022 | Feb 16, 2023 | |
| 2021 | Feb 17, 2022 | |
| 2020 | Feb 18, 2021 | |
| 2019 | Feb 21, 2020 | |
| 2018 | Feb 21, 2019 | |
| 2017 | Feb 15, 2018 | |
| 2016 | Feb 23, 2017 | |
| 2015 | Feb 18, 2016 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.